Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes
Artículo
Open/ Download
Publication date
2002-12-19Metadata
Show full item record
Cómo citar
Slater, Y.E.
Cómo citar
Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes
Author
Abstract
Cytisine (cy) is a potent and competitive partial agonist at α4 subunit-containing nicotinic acetylcholine (nACh) receptors while
at homomeric α7-nACh receptors it behaves as a full agonist with a relatively lower potency. In the present study, we assessed
the effects of bromination or iodination of the pyridone ring of cy and N-methylcytisine (N-Me-cy) on the effects of these compounds
on recombinant human (h) α7, hα4β2 and hα4β4 nACh receptors expressed in clonal cell lines and Xenopus oocytes. Halogenation
at C(3) of cy or N-Me-cy usually brings about a marked increase in both affinity and efficacy at hα7, hα4β2 and hα4β4 nACh,
the extent of which depends on whether the halogen is bromine or iodine, and upon receptor subtype. The effects of halogenation
at C(5) are strongly influenced by the specific halogen substituent so that bromination causes a decrease in both affinity and efficacy
while iodination decreases affinity but its effects on efficacy range from a decrease (hα7, hα4β4 nACh receptors) to a marked
increase (hα4β2 nACh receptors). Based on these findings, which differ from those showing that neither the affinity nor efficacy of
nicotine, 3-(2-azetidinylmethoxy)-pyridine or epibatidine are greatly affected by halogenation, dehalogenation or halogen exchange at
equivalent positions, we suggest that cy, N-Me-cy and their halo-isosteres bind to neuronal nACh receptors in a different orientation
allowing the halogen atom to interact with a hydrophobic halogen-accepting region within the predominantly hydrophobic agonistbinding
pocket of the receptors.
Patrocinador
This work was funded
in part by the Presidential Chair in Science (BKC; Chile,
1996) and ICM Grant no P99-031-F. BKC acknowledges
a generous gift of equipment from the Alexander von
Humboldt Foundation (Germany). ACV was the recipient
of a LANBIO scholarship. Funding from the Arizona
Disease Control Research Commission and the National
Institutes of Health (RJL) is also acknowledged.
Quote Item
Neuropharmacology, Vol. 44, p. 503–515, 2003.
Collections